Skip to content
2000
Volume 19, Issue 3
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune illness with an unclear etiology and a range of clinical manifestations. The therapeutic results of current conventional treatments are frequently unsatisfactory. Many B-cell-directed immunotherapies have recently been discovered, as B cells play a key role in the pathogenesis of SLE. However, large-scale rituximab trials found that the antibody against CD20 was no better than a placebo. Autologous CAR T-cell therapy has garnered considerable interest and is considered a potential treatment option for SLE. CD19+CD20- B cells are thought to play an essential role in the onset and progression of SLE. CD19-targeted CAR T-cells destroy B cells without requiring an accessory cell type, thereby decreasing B cells more efficiently. Preclinical trials of CAR T-cells in mice have shown promising results against SLE. The review aimed to shed light on autologous CD19-targeted CAR T-cells as a potential treatment for SLE.

Loading

Article metrics loading...

/content/journals/crr/10.2174/1573397119666230214103044
2023-08-01
2025-06-12
Loading full text...

Full text loading...

/content/journals/crr/10.2174/1573397119666230214103044
Loading

  • Article Type:
    Review Article
Keyword(s): B-cell; CAR T-cell therapy; CD19; potential; systemic lupus erythematosus; targeted
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test